Note to readers: An earlier version of this article stated that the House had yet to introduce compounding legislation in the new Congress. Rep. Ed Markey (D-MA) introduced a new compounding bill on May 23. The article has been corrected in the second and third paragraphs. We regret the error.
At a May 23 hearing on examining drug compounding held by the House Energy & Commerce Subcommittee on Health, the Republican majority saw the need for clarity on compounding oversight for FDA but wasn’t ready to go as far as the Senate compounding bill in providing the agency with more authority.
The two previous hearings in the House Energy & Commerce Committee were held by the Subcommittee on Oversight and Investigations. “Health holding a hearing means there is a greater likelihood that there will be legislation” emerging from the House Energy & Commerce Committee, said APhA Senior Lobbyist Michael Spira, who attended the hearing.
"One House Democrat has introduced compounding legislation in the new Congress, but it is unlikely to see the light of day because the House is controlled by Republicans who have discussed a differing approach,” Spira told pharmacist.com. The bill introduced by Rep. Ed Markey (D-MA) on May 23 updates previous legislation introduced in 2012.
Meanwhile, the Senate Health, Education, Labor, & Pensions (HELP) Committee’s Pharmaceutical Compounding Quality and Accountability Act (S. 959) was introduced on May 15 and combined with the Senate’s track-and-trace bill into one bill during a HELP Committee executive session on May 22. “Arguably, the Senate will take the bill up before the end of summer,” Spira said. (See June Pharmacy Today for more information on the Senate compounding bill.)
In related news, the full House on June 3 approved its track-and-trace bill on a voice vote. (See June Pharmacy Today for more information on the House and Senate track-and-trace bills.)